Overview

Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.

Status:
Completed

Trial end date:
2017-08-09

Target enrollment:

Participant gender:

Summary

To evaluate the change in quality of life (NEI VFQ 25) in subjects with DME during the first year of treatment with aflibercept according to the EU Label.

Phase:

Phase 4

Details

Lead Sponsor:

Bayer

Treatments:

Aflibercept